National Cancer Institute - NCI Division of Cancer Treatment and ...

This program has supported research at
every end of the discovery-developmentdelivery
continuum for imaging—from
the synthesis and early development of
novel imaging agents to development of
cutting-edge imaging hardware and software
and a number of pilot-phase clinical
studies. Topics have included innovative
in vivo cancer imaging technologies, novel
agents to detect cancerous and precancerous
processes, methods to display and
analyze in vivo images, and image-guided
treatments of cancer.
A review of 95 grants funded in fiscal years
1999 through 2003 reveals that 32, or 34
percent, have successfully transitioned to
larger NIH-funded programs.
Novel Technologies for
In Vivo Imaging
Program Announcements:
PA-06-045: http://grants.nih.gov/grants/
guide/pa-files/PA-06-045.html (STTR) and
PA-06-046: http://grants.nih.gov/grants/guide/
pa-files/PA-06-046.html (SBIR) and PA-04-095:
http://grants.nih.gov/grants/guide/pa-files/
PA-04-095.html (expiration date 11/2/2006)
Contacts:
Guoying Liu, Ph.D.—research in MRI, MRS,
and multimodalities
301-594-5220, liug@mail.nih.gov
Keyvan Farahani, Ph.D.—research in
image-guided therapy
301-451-2651, farahank@mail.nih.gov
James A. Deye, Ph.D.—research in
radiation therapy
301-496-6276, deyej@mail.nih.gov
Houston Baker, Ph.D.—other areas of research
301-594-9117, bakerhou@mail.nih.gov
Three program announcements comprise
the CIP initiative Novel Technologies for
In Vivo Imaging. Two are open to U.S. small
business applicants, PA-06-045 for STTR
and PA-06-046 for SBIR. The third, PA-04-
095, uses the R21/R33 grant mechanism.
It is modeled on the SBIR/STTR Fast Track,
but unlike the Fast Track, it is open to all
applicants. All three program announcements
encourage the development and
delivery of imaging tools and related
resources to support biomedical imaging
for cancer and other diseases. One motivation
is to facilitate multidisciplinary development
of novel imaging technologies for
risk assessment, early detection, screening,
diagnosis, and treatment. The program
also supports limited evaluation studies
that show proof-of-concept and clinical
functionality.
Another motivation for these program
announcements is shared with the NIHwide
Bioengineering Consortium (BECON)
committee’s efforts with the Bioengineering
Research Partnership (BRP) and
Bioengineering Research Grant (BRG)
R01 program announcements. BECON,
with CIP participation, seeks to expand
acceptance of engineering’s design-driven,
problem-solving approaches as a reasonable
addition to the hypothesis-driven and
mechanistic paradigms already well established
in most R01 study sections.
C A N C E R I M A G I N G P R O G R A M ■ 55